# A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults

> **NCT05142306** · PHASE1 · COMPLETED · sponsor: **Emergent BioSolutions** · enrollment: 23 (actual)

## Conditions studied

- SARS-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** COVID-HIG

## Key facts

- **NCT ID:** NCT05142306
- **Lead sponsor:** Emergent BioSolutions
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-07
- **Primary completion:** 2022-03-28
- **Final completion:** 2022-05-31
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05142306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05142306, "A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05142306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*